Quantification of pancreatic secretory trypsin inhibitor in colonic carcinoma and normal adjacent colonic mucosa

H Bohe, M Bohe, P Jönsson, C Lindström, K Ohlsson

Abstract

**Aims:** To measure the content of immunoreactive human pancreatic secretory trypsin inhibitor (irPSTI) in colonic carcinoma and adjacent normal colonic mucosa.

**Methods:** From a stable hybridoma cell line producing monoclonal antibodies specific for human PSTI, a specific enzyme linked immunosorbent assay (ELISA) for human PSTI was developed. In a precipitation assay system these antibodies bound human PSTI in a dose-dependent manner. The specimens were obtained from resectional surgery.

**Results:** The content of irPSTI was 19.9 μg/g protein (0.55 μg/g tissue wet weight) in colonic carcinoma. In adjacent normal colonic mucosa 43.6 μg/g protein (1.12 μg/g tissue wet weight) was shown.

**Conclusions:** The enzymatic degradation of surrounding tissue necessary for tumour cell invasion could be facilitated by this relative deficit of the inhibitor in infiltrative carcinoma.

(J Clin Pathol 1992;45:1066--1069)

Pancreatic secretory trypsin inhibitor (PSTI) was first isolated from pancreatic tissue in 1948 by Kazal. PSTI is thought to protect the pancreatic gland from damage by preactivated trypsin. The serum concentration of immunoreactive PSTI (irPSTI) is increased in severe diseases such as carcinoma of pancreatic gland, breast, thyroid, stomach, oesophagus, and gall bladder. irPSTI has also been shown in and isolated from different parts of the normal gastrointestinal mucosa. irPSTI has been found in the foveolar cells in the gastric mucosa. In duodenal and small intestinal mucosa irPSTI found in Paneth and goblet cells. Normal gall bladder mucosa did not contain irPSTI while well differentiated carcinoma and tissue resembling adenoma did.

In colonic mucosa irPSTI has been found in the goblet cells in the basal parts of the crypts. In colonic adenomas, however, irPSTI was also found in the upper parts of the polyps following the reverse mode of regeneration. irPSTI has not been shown in most colonic carcinoma tissue.

**Methods**

Electrophoresis reagents, dextran T500, protein A sepharose CL-4B, and CNBr-activated sepharose CL-4B were produced by Pharmacia LKB Biotechnology, Uppsala, Sweden. Class specific goat anti-mouse immunoglobulins were obtained from Nordic Immunologic Laboratories, Tilburg, the Netherlands. Alkaline phosphatase conjugated avidin was obtained from Dakopatts AB, Hägersten, Sweden. Tissue culture medium and fetal calf serum were supplied by Gibco Laboratories, Grand Island, New York, USA. Pansorbin was obtained from Calciobiochem Corporation, San Diego, California, USA. Recombinant PSTI (rPSTI) was obtained from Synergen Inc, Boulder, Colorado, USA. All other chemicals and proteins were purchased from Sigma Chemical Co, St Louis, Missouri, USA.

**Production of Monoclonal Antibodies**

BALB/c mice (Bomnice, Bomholtgård Breeding and Research Center Ltd, Bomholtvej, Denmark) were immunised by a subcutaneous injection of 30 μg of rPSTI in complete Freund’s adjuvant, repeated five times at three week intervals with 30 μg rPSTI in Freund’s incomplete adjuvant. Hybridomas were produced by fusion of SP2/0, non-secreting BALB/c myeloma cells with spleen lymphocytes from two out of five immunised mice. Selection of antibody-producing hybridomas

Hybridoma culture fluids were tested for antibody using solid phase ELISA technique. Microtitre plates were coated with 50 μl of rPSTI, 10 μg/ml. Hybridomas producing antibodies specific for PSTI were selected for cloning. The subclass type of the monoclonal antibodies produced was determined by the double immunodiffusion test. Cells harvested from cultures of hybridomas producing monoclonal antibodies against PSTI were injected intraperitoneally into BALB/c mice treated with Pristane (Aldrich, Beere, Belgium) for the production of ascites fluid. The ascites fluid was purified by affinity chromatography on a protein A sepharose CL-4B column equilibrated with 1·5 M glycine-NaOH, 3 M NaCl, at pH 8·9. The column was washed with this buffer after application of the ascites fluid and the IgG was eluted stepwise with 0·1 M citric acid-NaOH at pH 3·6.
Quantification of pancreatic secretory trypsin inhibitor in colonic tissue

Contents of trPSTI in normal colonic mucosa and colonic carcinoma

<table>
<thead>
<tr>
<th>µg trPSTI/µg protein</th>
<th>µg trPSTI/µg tissue wet weight</th>
<th>Differentiation of the adenocarcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal mucosa</td>
<td>Cancer</td>
<td>Normal mucosa</td>
</tr>
<tr>
<td>75.5</td>
<td>22.5</td>
<td>1.79</td>
</tr>
<tr>
<td>31.5</td>
<td>15.7</td>
<td>0.93</td>
</tr>
<tr>
<td>59.0*</td>
<td>14.5</td>
<td>1.59*</td>
</tr>
<tr>
<td>59.0*</td>
<td>11.1</td>
<td>1.59*</td>
</tr>
<tr>
<td>47.1</td>
<td>7.9</td>
<td>1.19</td>
</tr>
<tr>
<td>23.9</td>
<td>12.5</td>
<td>0.70</td>
</tr>
<tr>
<td>16.1</td>
<td>14.5</td>
<td>0.37</td>
</tr>
<tr>
<td>46.5</td>
<td>24.2</td>
<td>1.25</td>
</tr>
<tr>
<td>70.8</td>
<td>25.1</td>
<td>1.97</td>
</tr>
<tr>
<td>32.8</td>
<td>29.5</td>
<td>0.99</td>
</tr>
<tr>
<td>65.4</td>
<td>41.4</td>
<td>1.88</td>
</tr>
<tr>
<td>22.5</td>
<td>7.8</td>
<td>0.66</td>
</tr>
<tr>
<td>32.4</td>
<td>31.4</td>
<td>0.82</td>
</tr>
</tbody>
</table>

*One patient had two carcinomas.
colonic carcinomas). Clinical examination of the patients preoperatively did not reveal any other serious disease. From each resected colonic specimen one piece was taken from the carcinoma and one piece from the normal mucosa. The specimens were frozen and stored at −20°C for later analysis. The specimens were thawed and homogenised in four parts 0.05 M acetic acid with aprotinin (Trasylol) 500 KIU/ml. The homogenates were centrifuged 15000 × g for 10 minutes. The supernatants were collected. The precipitates were suspended in two parts acetic acid twice and centrifuged after each suspension. The three supernatant fluids were pooled and stored at −20°C until analysed with the above described ELISA and protein concentration by a modification of Lowry’s method. Histological evaluation was done according to WHO tumour classification and grading.11,12 The Wilcoxon matched-pairs signed ranks test was used for statistical analysis.

Results
The immunoprecipitation of PSTI by monoclonal antibodies showed a dose dependent binding of PSTI to the antibody. In the ELISA the intra-assay variation was 7% and the interassay variation was 13%. The lower limit of detection was 1 µg/l. The same recovery was obtained for PSTI in the tissue samples after dilution as after dilution of pure human PSTI (parallel dilution curves). The content of irPSTI in the specimens stated as µg/g protein and µg/g tissue wet weight is listed in the table. In all patients malignant tissue contained less irPSTI than the normal adjacent mucosa. The median content in carcinoma was 19-9 µg/g protein, range 7-8-41-4 (0-55 µg/g tissue wet weight, range 0-20-1-38). The content in normal colonic mucosa was 43-6 µg/g protein, range 16-1-75-5 (1-12 µg/g tissue wet weight, range 0-37-1-97). This difference was significant (p < 0-01).

Discussion
PSTI isolated from gastric, small intestinal, and colonic mucosa has been shown to be identical with that from pancreatic gland.7 19 In this study a specific monoclonal antibody against human PSTI was produced. With these antibodies an ELISA was developed for human PSTI. Analyses with this method in 12 patients with 13 colonic carcinomas showed that the median content of PSTI was lower in malignant than in normal colonic mucosa. Although there was an overlap in the range of tissue values, we universally found a lower PSTI content in malignant rather than in normal adjacent mucosa. These findings agree with our earlier findings of immunohistochemical staining results on specimens containing normal colonic mucosa, adenomas, and colonic carcinomas.4 11 In those studies irPSTI was shown in the basal parts of the crypts in normal colonic mucosa but rarely in colonic carcinomas. In polyps containing carcinomatous changes without infiltration of the muscularis mucosa, we noticed a shift from a high PSTI content in adenomatous epithelium to the carcinomatous epithelium where irPSTI was absent.9 10 This shift in content of irPSTI is difficult to explain. The apparent lack of the inhibitor could, however, be explained by increased consumption, because there is evidence to suggest that protease production is necessary for tumour cell invasion and that this proteolytic reaction takes place close to the tumour cell.19 22 Recently two tumour associated trypsinogen(s) were detected in ovarian carcinoma. These proteases were expressed together with tumour associated trypsin inhibitor (TATI).23 TATI is probably identical with PSTI.24 The explanation of increased consumption also agrees with the recently demonstrated PSTI mRNA in colorectal cancer.25 Gastrointestinal PSTI in normal and neoplastic mucosa may provide an important and hitherto unrecognised protective mechanism. Further studies are required to determine factors which control the secretion of gastrointestinal PSTI and its possible role in gastrointestinal mucosa and carcinoma.

This study was supported by the Swedish Cancer Society (Project No 1300-B89(04X)), the Medical Faculty, University of Lund, Albert Påhlsson’s foundation, Nils and Agnes Nilsson foundation, the foundation of Malmö General Hospital for Cancer and the foundation of the National Swedish Social Welfare Board.

Quantification of pancreatic secretory trypsin inhibitor in colonic tissue

Quantification of pancreatic secretory trypsin inhibitor in colonic carcinoma and normal adjacent colonic mucosa.

H Bohe, M Bohe, P Jönsson, C Lindström and K Ohlsson

doi: 10.1136/jcp.45.12.1066

Updated information and services can be found at:
[http://jcp.bmj.com/content/45/12/1066](http://jcp.bmj.com/content/45/12/1066)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)